NCT05835726View on ClinicalTrials.gov

Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

CompletedOBSERVATIONAL

Enrollment

188

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Multiple MyelomaDaratumumabAutologous Stem Cell TransplantationLeukapheresis

Interventions

DRUG

Daratumumab

NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.

Trial Locations (1)

00168

Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome

All Listed Sponsors

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT05835726 - Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. | Biotech Hunter | Biotech Hunter